- A20100I (See other available formats)
- Regulatory Status
- Other Names
- S1 RBD, Spike Protein RBD, S1 Receptor-binding Domain, Spike Receptor-binding Domain
- Mouse IgG2a, κ
- Ave. Rating
- Submit a Review
- Product Citations
|Cat #||Size||Price||Quantity Check Availability||Save|
SARS-CoV-2 is a respiratory virus which causes coronavirus disease 2019 (COVID-19). The corona virus spike (S) glycoprotein is a class I viral fusion protein on the outer envelope of the virion that plays a critical role in viral infection by recognizing host cell receptors and mediating fusion of the viral and cellular membranes. The S glycoprotein is synthesized as a precursor protein consisting of ~1,300 amino acids that is then cleaved into an amino (N)-terminal S1 subunit (~700 amino acids) and a carboxyl (C)-terminal S2 subunit (~600 amino acids). Three S1/S2 heterodimers assemble to form a trimer spike protruding from the viral envelope. The S1 subunit contains a receptor-binding domain (RBD) that can specifically bind to angiotensin converting enzyme 2 (ACE2), the receptor on target cells. Triggered by receptor binding, proteolytic processing and/or acidic pH in the cellular compartments, the class I viral fusion protein undergoes a transition from a metastable pre-fusion state to a stable post-fusion state during infection, in which the receptor-binding subunit is cleaved, and the fusion subunit under goes large-scale conformational rearrangements to expose the hydrophobic fusion peptide, induce the formation of a six-helix bundle, and bring the viral and cellular membranes close for fusion. The trimeric SARS coronavirus (SARS-CoV-2) S glycoprotein consisting of three S1-S2 heterodimers binds the cellular receptor angiotensin-converting enzyme 2 (ACE2) and mediates fusion of the viral and cellular membranes through a pre- to post-fusion conformation transition.Product Details
- Verified Reactivity
- Antibody Type
- Host Species
- 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxin level is < 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
- The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Block - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by blocking the binding of 0.5 µg/mL recombinant human ACE2 (Cat. No. 792002) to 1 µg/mL immobilized recombinant SARS-CoV-2 S protein RBD-Fc chimera (Cat. No. 793104). ND50 range: 0.05 - 0.25 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.
AB_2892509 (BioLegend Cat. No. 944803)
AB_2892509 (BioLegend Cat. No. 944804)
- Disulfide linked homodimer
- Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection
- Lung cells
- Biology Area
- Antigen References
1. Lu R, et al. 2020. Lancet. 395:565-574.
2. Li F. 2016. Annu Rev Virol. 29:237-261.
3. Belouzard S, et al. 2012. Viruses. 4:1011-33.
4. Song W, et al. 2018. PLoS Pathog. 14(8).
5. Li F, et al. 2020. Nature. 581:221-224.
- Gene ID
- View information about Viral Protein on UniProt.org
- Do you guarantee that your antibodies are totally pathogen free?
BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
- Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
- Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
No, BioLegend does not test for pathogens in-house unless otherwise indicated. However, we can recommend an outside vendor to perform this testing as needed.
- Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.
|Ultra-LEAF™ Purified anti-SARS-CoV-2 S Protein RBD||A20100I||Block|
Customers Also Purchased
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.